Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study

Hui Ju Ch'ang, Yu Lin Lin, Hsiu Po Wang, Yen Feng Chiu, Ming Chu Chang, Chih Hung Hsu, Yu Wen Tien, Jen Shi Chen, Ruey Kuen Hsieh, Pin Wen Lin, Yan Shen Shan, Ann Lii Cheng, Jang Yang Chang, Jacqueline Whang-Peng, Tsann Long Hwang, Li Tzong Chen

研究成果: 雜誌貢獻文章

13 引文 (Scopus)

摘要

Purpose: To evaluate the therapeutic efficacy of 3-month triplet induction chemotherapy (ICT) followed by concomitant chemoradiotherapy (CCRT) in patients with locally advanced pancreatic cancer (LAPC). Patients and Methods: Chemonaïve patients with measurable, histologically confirmed LAPC were eligible. The ICT consisted of biweekly gemcitabine (800 mg/m 2) infusion at a fixed dose rate (10 mg/m 2/min), followed by 85 mg/m 2 oxaliplatin and 48-h infusion of 5-fluorouracil/leucovorin (3000/150 mg/m 2) for 6 cycles. Patients without disease progression 4 weeks after ICT would receive weekly 400 mg/m 2 gemcitabine and 5040 cGy radiation in 28 fractions. After CCRT, patients were subjected for surgical intervention and/or maintenance chemotherapy until progression or intolerable toxicity. Results: Between December 2004 and August 2008, 50 patients were enrolled. The best responses after ICT were partial response (PR) in 9, stable disease in 26, and progressive disease or not evaluable in 15. Among the former 35 patients, 2 had disease progression before CCRT, and 3 declined to have CCRT. Of the 30 patients receiving CCRT, an additional 4 and 1 patient(s) achieved PR at the end of CCRT and during maintenance chemotherapy, respectively. On intent-to-treat analysis, the overall best response was PR in 14 patients and stable disease in 21. The overall response rate and disease control rate were 28% (95% confidence interval [CI], 16.2-42.5%) and 70% (95% CI, 44.4-99.2%), respectively. The median time to progression and overall survival of the intent-to-treat population was 9.3 (95% CI, 5.8-12.8) months and 14.5 (95% CI, 11.9-17.1) months, respectively. One- and two-year survival rates were 68% (95% CI, 55.1-80.9%) and 20.6% (95% CI, 8.7-32.5%), respectively. Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28% and 26.7%, respectively. Significant sensory neuropathy occurred in 9 patients (18%). Conclusion: Three months of triplet ICT followed by gemcitabine-based CCRT is feasible, moderately active, and associated with encouraging survival in patients with LAPC.
原文英語
期刊International Journal of Radiation Oncology Biology Physics
81
發行號5
DOIs
出版狀態已發佈 - 十二月 1 2011

指紋

oxaliplatin
gemcitabine
Induction Chemotherapy
Leucovorin
Taiwan
Chemoradiotherapy
chemotherapy
Pancreatic Neoplasms
Fluorouracil
induction
cancer
confidence
Confidence Intervals
intervals
progressions
Maintenance Chemotherapy
toxicity
maintenance
Disease Progression

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

引用此文

Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer : A Taiwan cooperative oncology group phase II study. / Ch'ang, Hui Ju; Lin, Yu Lin; Wang, Hsiu Po; Chiu, Yen Feng; Chang, Ming Chu; Hsu, Chih Hung; Tien, Yu Wen; Chen, Jen Shi; Hsieh, Ruey Kuen; Lin, Pin Wen; Shan, Yan Shen; Cheng, Ann Lii; Chang, Jang Yang; Whang-Peng, Jacqueline; Hwang, Tsann Long; Chen, Li Tzong.

於: International Journal of Radiation Oncology Biology Physics, 卷 81, 編號 5, 01.12.2011.

研究成果: 雜誌貢獻文章

Ch'ang, Hui Ju ; Lin, Yu Lin ; Wang, Hsiu Po ; Chiu, Yen Feng ; Chang, Ming Chu ; Hsu, Chih Hung ; Tien, Yu Wen ; Chen, Jen Shi ; Hsieh, Ruey Kuen ; Lin, Pin Wen ; Shan, Yan Shen ; Cheng, Ann Lii ; Chang, Jang Yang ; Whang-Peng, Jacqueline ; Hwang, Tsann Long ; Chen, Li Tzong. / Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer : A Taiwan cooperative oncology group phase II study. 於: International Journal of Radiation Oncology Biology Physics. 2011 ; 卷 81, 編號 5.
@article{79fb9c19024c4e459438226c3d8be99c,
title = "Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study",
abstract = "Purpose: To evaluate the therapeutic efficacy of 3-month triplet induction chemotherapy (ICT) followed by concomitant chemoradiotherapy (CCRT) in patients with locally advanced pancreatic cancer (LAPC). Patients and Methods: Chemona{\"i}ve patients with measurable, histologically confirmed LAPC were eligible. The ICT consisted of biweekly gemcitabine (800 mg/m 2) infusion at a fixed dose rate (10 mg/m 2/min), followed by 85 mg/m 2 oxaliplatin and 48-h infusion of 5-fluorouracil/leucovorin (3000/150 mg/m 2) for 6 cycles. Patients without disease progression 4 weeks after ICT would receive weekly 400 mg/m 2 gemcitabine and 5040 cGy radiation in 28 fractions. After CCRT, patients were subjected for surgical intervention and/or maintenance chemotherapy until progression or intolerable toxicity. Results: Between December 2004 and August 2008, 50 patients were enrolled. The best responses after ICT were partial response (PR) in 9, stable disease in 26, and progressive disease or not evaluable in 15. Among the former 35 patients, 2 had disease progression before CCRT, and 3 declined to have CCRT. Of the 30 patients receiving CCRT, an additional 4 and 1 patient(s) achieved PR at the end of CCRT and during maintenance chemotherapy, respectively. On intent-to-treat analysis, the overall best response was PR in 14 patients and stable disease in 21. The overall response rate and disease control rate were 28{\%} (95{\%} confidence interval [CI], 16.2-42.5{\%}) and 70{\%} (95{\%} CI, 44.4-99.2{\%}), respectively. The median time to progression and overall survival of the intent-to-treat population was 9.3 (95{\%} CI, 5.8-12.8) months and 14.5 (95{\%} CI, 11.9-17.1) months, respectively. One- and two-year survival rates were 68{\%} (95{\%} CI, 55.1-80.9{\%}) and 20.6{\%} (95{\%} CI, 8.7-32.5{\%}), respectively. Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28{\%} and 26.7{\%}, respectively. Significant sensory neuropathy occurred in 9 patients (18{\%}). Conclusion: Three months of triplet ICT followed by gemcitabine-based CCRT is feasible, moderately active, and associated with encouraging survival in patients with LAPC.",
keywords = "Maintenance chemotherapy, Multidisciplinary, Triplet chemotherapy",
author = "Ch'ang, {Hui Ju} and Lin, {Yu Lin} and Wang, {Hsiu Po} and Chiu, {Yen Feng} and Chang, {Ming Chu} and Hsu, {Chih Hung} and Tien, {Yu Wen} and Chen, {Jen Shi} and Hsieh, {Ruey Kuen} and Lin, {Pin Wen} and Shan, {Yan Shen} and Cheng, {Ann Lii} and Chang, {Jang Yang} and Jacqueline Whang-Peng and Hwang, {Tsann Long} and Chen, {Li Tzong}",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.ijrobp.2010.10.034",
language = "English",
volume = "81",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer

T2 - A Taiwan cooperative oncology group phase II study

AU - Ch'ang, Hui Ju

AU - Lin, Yu Lin

AU - Wang, Hsiu Po

AU - Chiu, Yen Feng

AU - Chang, Ming Chu

AU - Hsu, Chih Hung

AU - Tien, Yu Wen

AU - Chen, Jen Shi

AU - Hsieh, Ruey Kuen

AU - Lin, Pin Wen

AU - Shan, Yan Shen

AU - Cheng, Ann Lii

AU - Chang, Jang Yang

AU - Whang-Peng, Jacqueline

AU - Hwang, Tsann Long

AU - Chen, Li Tzong

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Purpose: To evaluate the therapeutic efficacy of 3-month triplet induction chemotherapy (ICT) followed by concomitant chemoradiotherapy (CCRT) in patients with locally advanced pancreatic cancer (LAPC). Patients and Methods: Chemonaïve patients with measurable, histologically confirmed LAPC were eligible. The ICT consisted of biweekly gemcitabine (800 mg/m 2) infusion at a fixed dose rate (10 mg/m 2/min), followed by 85 mg/m 2 oxaliplatin and 48-h infusion of 5-fluorouracil/leucovorin (3000/150 mg/m 2) for 6 cycles. Patients without disease progression 4 weeks after ICT would receive weekly 400 mg/m 2 gemcitabine and 5040 cGy radiation in 28 fractions. After CCRT, patients were subjected for surgical intervention and/or maintenance chemotherapy until progression or intolerable toxicity. Results: Between December 2004 and August 2008, 50 patients were enrolled. The best responses after ICT were partial response (PR) in 9, stable disease in 26, and progressive disease or not evaluable in 15. Among the former 35 patients, 2 had disease progression before CCRT, and 3 declined to have CCRT. Of the 30 patients receiving CCRT, an additional 4 and 1 patient(s) achieved PR at the end of CCRT and during maintenance chemotherapy, respectively. On intent-to-treat analysis, the overall best response was PR in 14 patients and stable disease in 21. The overall response rate and disease control rate were 28% (95% confidence interval [CI], 16.2-42.5%) and 70% (95% CI, 44.4-99.2%), respectively. The median time to progression and overall survival of the intent-to-treat population was 9.3 (95% CI, 5.8-12.8) months and 14.5 (95% CI, 11.9-17.1) months, respectively. One- and two-year survival rates were 68% (95% CI, 55.1-80.9%) and 20.6% (95% CI, 8.7-32.5%), respectively. Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28% and 26.7%, respectively. Significant sensory neuropathy occurred in 9 patients (18%). Conclusion: Three months of triplet ICT followed by gemcitabine-based CCRT is feasible, moderately active, and associated with encouraging survival in patients with LAPC.

AB - Purpose: To evaluate the therapeutic efficacy of 3-month triplet induction chemotherapy (ICT) followed by concomitant chemoradiotherapy (CCRT) in patients with locally advanced pancreatic cancer (LAPC). Patients and Methods: Chemonaïve patients with measurable, histologically confirmed LAPC were eligible. The ICT consisted of biweekly gemcitabine (800 mg/m 2) infusion at a fixed dose rate (10 mg/m 2/min), followed by 85 mg/m 2 oxaliplatin and 48-h infusion of 5-fluorouracil/leucovorin (3000/150 mg/m 2) for 6 cycles. Patients without disease progression 4 weeks after ICT would receive weekly 400 mg/m 2 gemcitabine and 5040 cGy radiation in 28 fractions. After CCRT, patients were subjected for surgical intervention and/or maintenance chemotherapy until progression or intolerable toxicity. Results: Between December 2004 and August 2008, 50 patients were enrolled. The best responses after ICT were partial response (PR) in 9, stable disease in 26, and progressive disease or not evaluable in 15. Among the former 35 patients, 2 had disease progression before CCRT, and 3 declined to have CCRT. Of the 30 patients receiving CCRT, an additional 4 and 1 patient(s) achieved PR at the end of CCRT and during maintenance chemotherapy, respectively. On intent-to-treat analysis, the overall best response was PR in 14 patients and stable disease in 21. The overall response rate and disease control rate were 28% (95% confidence interval [CI], 16.2-42.5%) and 70% (95% CI, 44.4-99.2%), respectively. The median time to progression and overall survival of the intent-to-treat population was 9.3 (95% CI, 5.8-12.8) months and 14.5 (95% CI, 11.9-17.1) months, respectively. One- and two-year survival rates were 68% (95% CI, 55.1-80.9%) and 20.6% (95% CI, 8.7-32.5%), respectively. Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28% and 26.7%, respectively. Significant sensory neuropathy occurred in 9 patients (18%). Conclusion: Three months of triplet ICT followed by gemcitabine-based CCRT is feasible, moderately active, and associated with encouraging survival in patients with LAPC.

KW - Maintenance chemotherapy

KW - Multidisciplinary

KW - Triplet chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=81855166622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855166622&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.10.034

DO - 10.1016/j.ijrobp.2010.10.034

M3 - Article

C2 - 21420250

AN - SCOPUS:81855166622

VL - 81

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -